NCT03948451View on ClinicalTrials.gov

Study Evaluating the Pharmacokinetic and Mass Balance of Single Dose [14C] AZD5718 in Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

April 30, 2019

Primary Completion Date

July 2, 2019

Study Completion Date

July 2, 2019

Conditions
Cardiovascular Disease
Interventions
DRUG

[14C]AZD5718 Oral Suspension

200 mg dose of \[14C\]AZD5718 Oral Suspension

Trial Locations (1)

NG11 6JS

Research Site, Ruddington

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
collaborator

Quotient Sciences

INDUSTRY

lead

AstraZeneca

INDUSTRY

NCT03948451 - Study Evaluating the Pharmacokinetic and Mass Balance of Single Dose [14C] AZD5718 in Volunteers | Biotech Hunter | Biotech Hunter